AR098991A1 - Compuestos de nicotinamida sustituida con heteroarilo - Google Patents
Compuestos de nicotinamida sustituida con heteroariloInfo
- Publication number
- AR098991A1 AR098991A1 ARP140104949A ARP140104949A AR098991A1 AR 098991 A1 AR098991 A1 AR 098991A1 AR P140104949 A ARP140104949 A AR P140104949A AR P140104949 A ARP140104949 A AR P140104949A AR 098991 A1 AR098991 A1 AR 098991A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- fluoroalkyl
- nhc
- ch2nhc
- fluoroalkylene
- Prior art date
Links
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical class NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 1
- -1 pyrrolo [2,3-b] pyridinyl Chemical group 0.000 abstract 29
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 28
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 16
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 10
- 125000005466 alkylenyl group Chemical group 0.000 abstract 9
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 8
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000003566 oxetanyl group Chemical group 0.000 abstract 6
- 125000002757 morpholinyl group Chemical group 0.000 abstract 5
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 5
- 125000004076 pyridyl group Chemical group 0.000 abstract 5
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000002883 imidazolyl group Chemical group 0.000 abstract 4
- 125000003386 piperidinyl group Chemical group 0.000 abstract 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 abstract 2
- 125000006712 (C1-C4) deuteroalkyl group Chemical group 0.000 abstract 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- IGVGARQHWLUJIO-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1,3-benzothiazol-2-amine Chemical compound C1C=CC=C2SC(N)NC21 IGVGARQHWLUJIO-UHFFFAOYSA-N 0.000 abstract 1
- 125000005899 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- NIZFPIBTGJOVRT-UHFFFAOYSA-N bicyclo[2.2.1]heptan-4-ol Chemical compound C1CC2CCC1(O)C2 NIZFPIBTGJOVRT-UHFFFAOYSA-N 0.000 abstract 1
- 125000006390 chloropyrimidinyl group Chemical group 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000005345 deuteroalkyl group Chemical group 0.000 abstract 1
- 125000004212 difluorophenyl group Chemical group 0.000 abstract 1
- 125000001207 fluorophenyl group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000004306 triazinyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
También se describen el uso de tales compuestos como moduladores de IRAK4, y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles para tratar, prevenir o ralentizar enfermedades inflamatorias y autoinmunitarias. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) o una sal de aquel, en donde: HET es un heteroarilo seleccionado de pirazolilo, indolilo, pirrolo[2,3-b]piridinilo, pirrolo[2,3-d]pirimidinilo, pirazolo[3,4-b]piridinilo, pirazolo[3,4-d]pirimidinilo, 2,3-dihidro-1H-pirrolo[2,3-b]piridinilo, imidazo[4,5-b]piridinilo y purinilo, en donde el heteroarilo se sustituye con Rᵃ y Rᵇ; Rᵃ es H, F, Cl, Br, -CN, -OH, C₁₋₄ alquilo, C₁₋₄ fluoroalquilo, C₁₋₄ hidroxialquilo, C₁₋₄ alcoxi, -NH₂, -NH(C₁₋₄ alquilo), -N(C₁₋₄ alquilo)₂, -NH(C₁₋₄ hidroxialquilo), -NH(C₁₋₄ fluoroalquilo), -NH(C₁₋₆ hidroxi-fluoroalquilo), -C(O)NH₂, -CH₂NHC(O)(C₁₋₆ alquilo), -CH₂NHC(O)(C₁₋₆ hidroxialquilo), -CH₂NHC(O)NH(C₁₋₆ alquilo), -CH₂NHC(O)NHCH₂(fenilo), -CH₂NHC(O)N(C₁₋₄ alquilo)₂, -CH₂NHC(O)O(C₁₋₄ alquilo), -CH₂NHC(O)(C₃₋₈ cicloalquilo), -CH₂NHC(O)(tetrahidrofuranilo), -CH₂NHC(O)CH₂(C₃₋₆ cicloalquilo), -CH₂NHC(O)CH₂(tetrahidropiranilo), -CH₂NHC(O)CH₂(fenilo), -NHC(O)(C₁₋₄ alquilo), pirrolidinilo, hidroxipirrolidinilo o piridazinilo; Rᵇ es H o -NH₂; R¹ es: (i) C₁₋₆ alquilo, C₁₋₆ fluoroalquilo, C₁₋₆ hidroxialquilo, C₁₋₈ hidroxi-fluoroalquilo,-(C₁₋₆ alquilenil)O(C₁₋₄ alquilo), -(C₁₋₆ alquilenil)O(C₁₋₄ fluoroalquilo), -(C₁₋₆ fluoroalquilenil)O(C₁₋₄ alquilo), -(C₁₋₆ fluoroalquilenil)O(C₁₋₄ deuteroalquilo), -(C₁₋₆ fluoroalquilenil)O(C₁₋₄ fluoroalquilo), -(C₁₋₄ fluoroalquilenil)C(C₃₋₆ cicloalquil)₂(OH), -(C₁₋₄ alquilenil)NHC(O)(C₁₋₄ alquilenil)OC(O)(C₁₋₃ alquilo), -(C₁₋₆ alquilenil)NHS(O)₂(C₁₋₄ alquilo), -(C₁₋₆ alquilenil)P(O)(C₁₋₄ alcoxi)₂, -(C₁₋₆ fluoroalquilenil)NH(C₁₋₄ alquilo), -(C₁₋₆ alquilenil)C(O)NH(C₁₋₄ alquilo), -(C₁₋₆ fluoroalquilenil)C(O)NH(C₁₋₄ alquilo), -(C₁₋₆ fluoroalquilenil)C(O)NH(C₁₋₄ hidroxialquilo) o -(C₁₋₆ fluoroalquilenil)OP(O)(OH)₂; (ii) -(C₁₋₃, alquilenil)Rˣ, -(C₁₋₃ fluoroalquilenil)Rˣ, -(C₁₋₃ alquilenil)C(O)Rˣ, -(C₁₋₃ alquilenil)C(O)NHRˣ, -(C₁₋₃, fluoroalquilenil)C(O)Rˣ o CH₂CF=(tetrahidropiranilo), en donde Rˣ es un grupo cíclico seleccionado de C₃₋₆ cicloalquilo, tetrazolilo, 1,1-dioxidotetrahidrotiofenilo, 1,1-dioxidotiomorfolinilo, oxadiazolilo, piperidinilo, piperazinilo, pirrolidinilo, oxetanilo, tetrahidrofuranilo, tetrahidropiranilo, piridinilo, imidazolilo, morfolinilo, fenilo y triazinilo, en donde cada grupo cíclico se sustituye con 0 a 3 sustituyentes seleccionados independientemente de F, -OH, -CH₃, -C(CH₂)₂OH, -OCH₃, -C(O)CH₂CN, -S(O)₂CH₃, -S(O)₂NH₂, -NHC(O)CH₃, -N(S(O)₂CH₃)₂, -CH₂CH₂(acetamidofenilo), -CH₂CH₂(metoxifenilo), -CH₂CH₂(sulfamoilfenilo), oxetanilo, bencilo y morfolinilo; (iii) C₃₋₆ cicloalquilo o C₄₋₆ cicloalquenilo, cada uno sustituido con 0 a 3 sustituyentes seleccionados independientemente de F, -OH, -CN, C₁₋₃ alquilo, C₁₋₃ alcoxi, -S(C₁₋₃ alquilo), -NO₂, -S(O)₂(C₁₋₃ alquilo), C₁₋₄ hidroxialquilo, -C(C₁₋₃ alquil)(OH)(C₃₋₆ cicloalquilo), -CH₂C(O)NH(C₁₋₃ alquilo), -NHC(O)(C₁₋₃ alquilo), -NHC(O)(C₁₋₄ hidroxialquilo), -C(O)NH(C₁₋₃ alquilo), -C(O)NH(C₁₋₃ deuteroalquilo), -C(O)NH(C₃₋₆ cicloalquilo), -NHC(O)O(C₁₋₃ alquilo), -NHS(O)₂(C₁₋₃ alquilo), piridinilo, imidazolilo, pirazolilo, metilimidazolilo, metilpirazolilo y tiazolilo; (iv) tetrahidropiranilo, piperidinilo, pirazolilo, fenilo, piridinilo o pirimidinilo, cada uno sustituido con 0 a 1 sustituyente seleccionado de -OH, C₁₋₃ alquilo, C₁₋₃ fluoroalquilo, C₁₋₄ hidroxialquilo, C₁₋₃ alcoxi, -C(O)(C₁₋₄ alquilo), -S(O)₂(C₁₋₄ alquilo), -S(O)₂NH(C₁₋₄ alquilo), -NH(C₁₋₃ alquilo), -N(C₁₋₃ alquilo)₂, -O(C₁₋₃ alquilenil)N(C₁₋₃ alquilo)₂, -CH₂(morfolinilo), acetidinilo, oxetanilo, tetrahidropiranilo, morfolinilo, piperazinilo, piperidinilo, metilpiperazinilo, metoxipiperidinilo, piridinilo, pirimidinilo, metilsulfonilo acetidinilo y -C(O)(acetidinilo de metilsulfonilo); o (v) pirrolo[2,3-c]piridinilo, biciclo[2.2.1]heptan-1-ol, tetrahidrobenzo[d]tiazol-2-amina o 1,3-diazaspiro[4.5]decan-2,4-diona; y R² es (i) C₁₋₇ alquilo o C₂₋₆ alquenilo, cada uno sustituido con 0 a 3 sustituyentes seleccionados independientemente de F, -OH y -CN; -(C₁₋₄ alquilenil)O(C₁₋₄ alquilo), -(C₁₋₄ alquilenil)O(C₁₋₄ fluoroalquilo), -(C₁₋₆ alquilenil)NH₂, -(C₁₋₆ alquilenil)S(O)₂(C₁₋₃ alquilo), -(C₁₋₆ fluoroalquilenil)NH(C₁₋₃ alquilo) o -(C₁₋₆ alquilenil)NHC(O)(C₁₋₄ fluoroalquilo); (ii) -(C₁₋₄ alquilenil)Rʸ, en donde Rʸ es C₃₋₆ cicloalquilo, acetidinilo, oxetanilo, oxazolilo, piridinilo, tetrahidropiranilo o morfolinilo, cada uno sustituido con o a 2 sustituyentes seleccionados independientemente de F, OH y C₁₋₃ alquilo; (iii) C₃₋₆ cicloalquilo, acetidinilo, oxetanilo, furanilo, tetrahidrofuranilo, pirrolidinilo, piperidinilo o tetrahidropiranilo, cada uno sustituido con 0 a 3 sustituyentes seleccionados independientemente de F, -OH, C₁₋₃ alquilo, C₁₋₃, hidroxialquilo, -C(O)(C₁₋₃ alquilo), -C(O)(C₁₋₃ fluoroalquilo), -C(O)(C₁₋₃ cianoalquilo), -C(O)O(C₁₋₃ alquilo), -C(O)NH₂, -C(O)NH(C₁₋₃ alquilo), -C(O)(difluorofenilo), -NH₂, -NH(C₁₋₃ alquilo), -NH(C₁₋₃ fluoroalquilo), -NH(oxetanilo), -NHC(O)(C₁₋₃ alquilo), -NHC(O)(C₁₋₃ fluoroalquilo), -NHC(O)(C₃₋₆ cicloalquilo), -NHC(O)(fluorofenilo), -S(O)₂(C₁₋₃ alquilo), imidazolilo, fenilo, pirimidinilo, fluoropirimidinilo, cloropirimidinilo y metoxipirimidinilo; (iv) adamantanilo, hidroxiadamantanilo, benzo[d]imidazolilo, benzo[d]oxazolilo, benzo[d]triazolilo, benzotiazolilo, biciclo[1.1.1]pentanilo o hidroxibiciclo[2.2.1]heptanilo; o (v) fenilo, pirazolilo, tiazolilo, tiadiazolilo o indazolilo, cada uno sustituido con 0 a 2 sustituyentes seleccionados independientemente de F, Cl, -OH, -CN, C₁₋₄ alquilo, C₁₋₄ hidroxialquilo, C₁₋₄ fluoroalquilo, C₁₋₄ cianoalquilo, C₁₋₃ alcoxi, C₃₋₆ cicloalquilo, -(C₁₋₃ alquilenil)O(C₁₋₃ alquilo), -(C₁₋₃ alquilenil)O(C₁₋₃ fluoroalquilo), -C(O)NH₂, -C(O)NH(C₁₋₃ alquilo), -NHC(O)(C₁₋₃ alquilo), -NHC(O)S(O)₂(C₁₋₃ alquilo), -S(O)₂NH₂, -S(O)₂(C₁₋₃ alquilo), pirazolilo, metilpirazolilo, imidazolilo, triazolilo, metiltetrazolilo, etiltetrazolilo, fenilo, pirimidinilo, fluoropirimidinilo y tetrahidropiranilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461923403P | 2014-01-03 | 2014-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098991A1 true AR098991A1 (es) | 2016-06-22 |
Family
ID=52355270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104949A AR098991A1 (es) | 2014-01-03 | 2014-12-29 | Compuestos de nicotinamida sustituida con heteroarilo |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9169252B2 (es) |
| EP (1) | EP3089973B1 (es) |
| JP (1) | JP6475252B2 (es) |
| KR (1) | KR20160101191A (es) |
| CN (1) | CN106061967B (es) |
| AR (1) | AR098991A1 (es) |
| AU (1) | AU2015204045A1 (es) |
| CA (1) | CA2935329A1 (es) |
| CL (1) | CL2016001706A1 (es) |
| EA (1) | EA201691343A1 (es) |
| ES (1) | ES2804707T3 (es) |
| IL (1) | IL246474A0 (es) |
| MA (1) | MA39162A1 (es) |
| MX (1) | MX2016008723A (es) |
| PE (1) | PE20161292A1 (es) |
| PH (1) | PH12016501164A1 (es) |
| SG (1) | SG11201605340QA (es) |
| TN (1) | TN2016000271A1 (es) |
| TW (1) | TW201609693A (es) |
| UY (1) | UY35935A (es) |
| WO (1) | WO2015103453A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2615302T3 (es) | 2012-11-08 | 2017-06-06 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heteroarilo útiles como modulares de cinasa |
| TW201422606A (zh) | 2012-11-08 | 2014-06-16 | 必治妥美雅史谷比公司 | 可作爲激酶調節劑之經雙環雜環取代之吡啶化合物 |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| PL3089971T3 (pl) | 2014-01-01 | 2021-01-25 | Medivation Technologies Llc | Związki i sposoby ich zastosowania |
| TW201718571A (zh) | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| TW201713655A (zh) * | 2015-06-24 | 2017-04-16 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| JP6720225B2 (ja) * | 2015-06-24 | 2020-07-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリール置換のアミノピリジン化合物 |
| GB201518456D0 (en) * | 2015-10-19 | 2015-12-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
| WO2017133657A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| WO2017133667A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| JOP20180011A1 (ar) * | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| US11130756B2 (en) * | 2017-08-04 | 2021-09-28 | Bristol-Myers Squibb Company | [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds |
| MX2020002944A (es) | 2017-09-14 | 2020-09-28 | Daiichi Sankyo Co Ltd | Compuesto que tiene estructura ciclica. |
| IL273432B (en) | 2017-09-22 | 2022-09-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| TW201927769A (zh) * | 2017-12-18 | 2019-07-16 | 德商歌林達有限公司 | 經取代之吡咯啶醯胺ｉｉ |
| US10874743B2 (en) * | 2017-12-26 | 2020-12-29 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CA3090275A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| TWI721483B (zh) * | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| TWI727392B (zh) * | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| JP2022516401A (ja) | 2018-11-30 | 2022-02-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| TW202136251A (zh) | 2019-12-17 | 2021-10-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4393489A1 (en) * | 2021-07-29 | 2024-07-03 | Provibio Co., Ltd. | Novel benzene derivative and immunosuppression-related use thereof |
| CN117813307A (zh) | 2021-08-18 | 2024-04-02 | 新锐思生物制药股份有限公司 | 白介素-1受体相关激酶的双官能降解物及其治疗用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7273868B2 (en) * | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| EP1399440B1 (en) | 2001-06-15 | 2009-06-03 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| MXPA04012855A (es) | 2002-06-28 | 2005-04-19 | Yamanouchi Pharma Co Ltd | Derivado de diaminopirimidincarboxiamida. |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| CA2685588A1 (en) | 2007-06-08 | 2008-12-11 | Bayer Cropscience Sa | Fungicide heterocyclyl-pyrimidinyl-amino derivatives |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| EA021367B1 (ru) * | 2008-11-28 | 2015-06-30 | Кова Компани, Лтд. | Производное пиридин-3-карбоксамида |
| CN102458402B (zh) * | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
| EP2493863B1 (en) | 2009-10-30 | 2015-02-25 | Janssen Pharmaceutica NV | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| US20190192510A1 (en) | 2010-02-01 | 2019-06-27 | Nippon Chemiphar Co., Ltd. | Gpr119 agonist |
| US20140142094A1 (en) | 2011-04-29 | 2014-05-22 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitors |
| US9074384B2 (en) * | 2011-07-27 | 2015-07-07 | Intex Recreation Corp. | Combined swimming pool ladder structure |
| WO2013106612A1 (en) * | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| US9242976B2 (en) | 2012-01-13 | 2016-01-26 | Bristol-Myers Squibb Company | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| CN104169275B (zh) | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
| ES2615302T3 (es) * | 2012-11-08 | 2017-06-06 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heteroarilo útiles como modulares de cinasa |
| TW201422606A (zh) * | 2012-11-08 | 2014-06-16 | 必治妥美雅史谷比公司 | 可作爲激酶調節劑之經雙環雜環取代之吡啶化合物 |
| BR112015010244A8 (pt) | 2012-11-08 | 2019-10-01 | Bristol Myers Squibb Co | compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso |
-
2014
- 2014-12-29 AR ARP140104949A patent/AR098991A1/es unknown
- 2014-12-29 TW TW103146137A patent/TW201609693A/zh unknown
- 2014-12-29 UY UY0001035935A patent/UY35935A/es unknown
-
2015
- 2015-01-02 EA EA201691343A patent/EA201691343A1/ru unknown
- 2015-01-02 EP EP15700518.2A patent/EP3089973B1/en active Active
- 2015-01-02 US US14/588,470 patent/US9169252B2/en active Active
- 2015-01-02 MX MX2016008723A patent/MX2016008723A/es unknown
- 2015-01-02 KR KR1020167020884A patent/KR20160101191A/ko not_active Application Discontinuation
- 2015-01-02 CA CA2935329A patent/CA2935329A1/en not_active Abandoned
- 2015-01-02 PE PE2016000991A patent/PE20161292A1/es not_active Application Discontinuation
- 2015-01-02 TN TN2016000271A patent/TN2016000271A1/en unknown
- 2015-01-02 JP JP2016544410A patent/JP6475252B2/ja active Active
- 2015-01-02 MA MA39162A patent/MA39162A1/fr unknown
- 2015-01-02 SG SG11201605340QA patent/SG11201605340QA/en unknown
- 2015-01-02 ES ES15700518T patent/ES2804707T3/es active Active
- 2015-01-02 WO PCT/US2015/010006 patent/WO2015103453A1/en active Application Filing
- 2015-01-02 CN CN201580011617.6A patent/CN106061967B/zh active Active
- 2015-01-02 AU AU2015204045A patent/AU2015204045A1/en not_active Abandoned
-
2016
- 2016-06-16 PH PH12016501164A patent/PH12016501164A1/en unknown
- 2016-06-27 IL IL246474A patent/IL246474A0/en unknown
- 2016-07-01 CL CL2016001706A patent/CL2016001706A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12016501164A1 (en) | 2016-08-15 |
| IL246474A0 (en) | 2016-08-31 |
| CN106061967B (zh) | 2019-04-19 |
| SG11201605340QA (en) | 2016-07-28 |
| TW201609693A (zh) | 2016-03-16 |
| EP3089973B1 (en) | 2020-04-29 |
| WO2015103453A1 (en) | 2015-07-09 |
| EA201691343A1 (ru) | 2016-11-30 |
| PE20161292A1 (es) | 2016-11-23 |
| MX2016008723A (es) | 2016-09-07 |
| TN2016000271A1 (en) | 2017-10-06 |
| ES2804707T3 (es) | 2021-02-09 |
| JP2017501202A (ja) | 2017-01-12 |
| US9169252B2 (en) | 2015-10-27 |
| CA2935329A1 (en) | 2015-07-09 |
| UY35935A (es) | 2015-06-30 |
| AU2015204045A1 (en) | 2016-08-18 |
| CL2016001706A1 (es) | 2017-02-10 |
| US20150191464A1 (en) | 2015-07-09 |
| KR20160101191A (ko) | 2016-08-24 |
| EP3089973A1 (en) | 2016-11-09 |
| JP6475252B2 (ja) | 2019-02-27 |
| MA39162A1 (fr) | 2017-12-29 |
| CN106061967A (zh) | 2016-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098991A1 (es) | Compuestos de nicotinamida sustituida con heteroarilo | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR105113A1 (es) | Compuestos de aminopiridina sustituida con heteroarilo | |
| AR100340A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR110421A1 (es) | Derivados de pirazol como inhibidores de malt1 | |
| AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
| AR105114A1 (es) | Compuestos de aminopiridina sustituida con heteroarilo | |
| AR095423A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
| AR108875A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR095280A1 (es) | Derivados heterocíclicos de imidazo[1,2-a]piridina | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR076264A1 (es) | Triazolopiridinas sustituidas y analogos de estas | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR105112A1 (es) | Compuestos de aminopiridina sustituida con heteroarilo | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR096149A1 (es) | Macrociclos como inhibidores de quinasa | |
| AR112264A1 (es) | Derivados de oxoftalazina y oxocinolina como antagonistas de los receptores s1p, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades fibróticas, autoinmunes y proliferativas | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
| AR111808A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| AR102217A1 (es) | Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| AR093512A1 (es) | Derivados heterociclicos como moduladores de la actividad de cinasas | |
| PE20190980A1 (es) | Compuestos terapeuticos y metodos para utilizarlos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |